Annexon
IPO
Unlocking the Next Generation of Complement Therapies
- Headquarters
- South San Francisco, California
- Founded
- 2011
- Business Model
- B2B
- Website
- annexonbio.com
- Last Round
- Series ENov 2025
About
Annexon Biosciences (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic diseases. The company targets C1q, the initiating molecule of the classical complement pathway, to block all damaging downstream components. Its lead programs address Guillain-Barré Syndrome, geographic atrophy, and other complement-driven diseases.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account